Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class III · Low risk Ongoing Initiated Dec 22, 2025 (10 months ago)

Diclofenac Sodium Topical Gel

Class III — Low risk. Unlikely to cause harm, but violates FDA regulations.

Why it was recalled

Failed PH Specifications

Cause type: Failed specification

A physical or chemical test other than potency, dissolution, impurity or stability failed - pH, viscosity, appearance, tablet integrity, fill volume. A product outside its own specification may not perform as designed, even if the active ingredient is present. All failed specification recalls.

What was recalled

Diclofenac Sodium Topical Gel, 1%, NET WT 100 g (3.53 oz), Manufactured by: DPT Laboratories, Ltd., 307 E Josephine Street, San Antonio, TX 78215. NDC: 76282-103-39

Affected NDC 76282-0103-39

Compare with the code on your package — it is the most precise check available.

Drug: Diclofenac Category: Pain Relief & OTC Medication

Product details

From the FDA NDC directory, for the product code this recall names. Compare with the label on your package.

ProductStrengthForm & routeLabelerType
Diclofenac Sodium
NDC 76282-0103
10 mg/g Gel
Topical
Exelan Pharmaceuticals INC. OTC
Recalling firm
Cipla USA, Inc.
Origin
NJ, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0291-2026 · FDA notice

Low risk, still worth a check. Class III means the product is unlikely to cause harm but breaks an FDA rule (often labeling). If your lot matches, your pharmacy will normally swap it; there is no need for alarm.

Other Diclofenac recalls

See all
Class II · Moderate risk

Diclofenac Sodium

Failed Viscosity Specifications: Out of Specification (OOS) [slightly lower than the limit] result in viscosity for Diclofenac Sodium Gel, 3%.

Ongoing Failed specification Sun Pharmaceutical Industries INC NDC 51672-1363-7 D-0342-2026
Class II · Moderate risk

Diclofenac Sodium Topical Solution 1.5% w/w

CGMP Deviations: all products within expiry are being recalled because the manufacturing firm, Teligent Pharma, Inc. is discontinuing its stability study program.

Terminated Stability / shelf life Preferred Pharmaceuticals, Inc. NDC 68788-7918-01 D-0773-2022

Other recalls by Cipla USA, Inc.

All 2025 recalls